Clay Siegall, President and CEO of the cancer drug company Seattle Genetics, is making a name not only for his company but also himself. Seattle Genetics is but one company in the Puget Sound region that is involved in cancer research. This region’s high concentration of such companies is in part why Vice President Joe Biden decided to visit the area and learn more about developments in this important industry. The visit from our nation’s Second in Command helped to highlight the advancements and future goals of Siegall’s Seattle Genetics.
In particular, the company is expanding testing of Adcetris, which is its sole commercialized drug. The drug is focused on fighting different types of lymphoma, and more than seventy trials are underway to research fighting this debilitating disease. Of particular excitement surrounding the company is the Phase 3 trial being conducted that is using Adcetris as the main treatment for newly diagnosed or untreated Hodgkin Lymphoma. The drug has already proven to be a success in treating other lymphomas. Last year Adcetris earned the company $226 million in sales within the United States and Canada.
Adcetris is be the main drug for Clay Siegall’s company right now, but he has ambitious plans for even more drug advancements. Some of these drugs will treat forms of leukemia and breast cancer, while two of the new drugs will fight cancer of the bladder. Siegall would like to add an additional one hundred employees to help the already eight hundred researchers employed by the company.
Clay Siegall is no novice in the cancer drug industry. In addition to being a businessman, he is a Doctor. Siegall earned a B.S. degree in Zoology from the University of Maryland before going on to complete a Ph.D in Genetics from George Washington University. Since co-founding Seattle Genetics over three decades ago, Dr. Siegall has raised over $330 million for the company’s research and development activities.
In addition to his current role, he holds a position on the Board of Directors of privately held Alder BioPharmaceuticals and the Washington Biotechnology and Biomedical Association. Given Siegall’s education and business background, new and exciting developments can be expected from his ventures.